Subscribe

  • How Can We Help You?

    Global Problem Solving from Covington: Deal with Complex Problems Anywhere in the World

Kyle Rabe

Partner

Washington +1 202 662 5736

  • About
  • Representative Matters
  • Credentials
  • About

    Kyle represents both U.S. and international clients in mergers and acquisitions, joint ventures and other corporate transactions.

    Kyle regularly advises clients in the life sciences industry in connection with buy-side and sell-side mergers and acquisitions transactions, including multi-billion dollar acquisitions of public companies. He also represents clients in a variety of other industries, including technology, energy and consumer products.

    He also serves as co-chair of Covington’s multidisciplinary Digital Health Initiative.

    Kyle is a member of the Bar of New York. District of Columbia bar application pending; supervised by principals of the firm.

    Areas of Expertise

  • Practices and Industries
  • Representative Matters
    • UCB in its:
      • $1.9 billion acquisition of Zogenix (NASDAQ: ZGNX);
      • $2.1 billion acquisition of Ra Pharmaceuticals (NASDAQ:RARX);
      • sale of Kremers Urban Pharmaceuticals to Lannett; and
      • acquisition of midazolam nasal spray from Proximagen.
    • Rogers Corporation (NYSE: ROG) in its pending $5.2 billion acquisition by DuPont.
    • Johnson & Johnson in various acquisitions and divestitures, including its:
      • acquisition of OrthoSpin;
      • acquisition of Olive Medical;
      • acquisition of 3D printing technologies from Tissue Regeneration Systems;
      • sale of Prodisc; and
      • sale of RoC Skincare.
    • Merck in its $425 million acquisition of OncoImmune.

    • Allergan in its:
      • $2.1 billion acquisition of Kythera Biopharmaceuticals (NASDAQ: KYTH);
      • acquisition of Bonti;
      • acquisition of Chase Pharmaceuticals;
      • acquisition of ForSight VISION5; and
      • acquisition of Akarna Therapeutics.
    • Abbvie in its $5.8 billion acquisition of Stemcentrx.
    • AstraZeneca in its up to $4.3 billion acquisition of Bristol-Myers Squibb's interests in the companies’ diabetes alliance.
    • Salix Pharmaceuticals in its $2.6 billion acquisition of Santarus (NASDAQ: SNTS).
    • King Pharmaceuticals (NYSE: KG) in its $3.6 billion merger with Pfizer.
    • SK Holdings in its acquisition of a significant minority interest in Eureka Midstream.
    • Aristocrat Leisure Limited in its $1.28 billion acquisition of Video Gaming Technologies.

    Areas of Expertise

  • Credentials
    Education
    • University of Virginia School of Law, J.D., 2009
    • London School of Economics, M.Sc., 2004
    • Georgetown University, B.A., 2003
    Bar Admissions
    • DC Application Pending
    • Supervised by DC Firm Principals
    • New York
    Accolades
    • New York Super Lawyers, Mergers & Acquisitions "Rising Star" (2012-2021)
    Previous Experience
    • U.S. Senate Committee on Foreign Relations, Staff Assistant (2005-2006)

    Areas of Expertise

News and Insights

Events